EHA 2014 | Impressive results from phase 3 RESONATE trial in CLL
Prof Peter Hillmen from Leeds Teaching Hospital, Leeds, UK, gives an update on the results of the phase 3 RESONATE trial of 391 patients with relapsed or refractory chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL). Prof Hillmen outlines the progression-free and overall survival results which showed the significant benefits of ibrutinib over ofatumumab. He comments on single versus combination therapy with ibrutinib in CLL.
Get great new content delivered to your inboxSign up